Your browser doesn't support javascript.
loading
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study.
Shimozaki, Keitaro; Nakayama, Izuma; Takahari, Daisuke; Nagashima, Kengo; Yoshino, Koichiro; Fukuda, Koshiro; Fukuoka, Shota; Osumi, Hiroki; Ogura, Mariko; Wakatsuki, Takeru; Ooki, Akira; Shinozaki, Eiji; Chin, Keisho; Yamaguchi, Kensei.
Afiliación
  • Shimozaki K; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Nakayama I; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Takahari D; Department of Gastroenterology, Kawasaki Municipal Hospital, Kawasaki, Japan.
  • Nagashima K; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yoshino K; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. daisuke.takahari@jfcr.or.jp.
  • Fukuda K; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
  • Fukuoka S; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Osumi H; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ogura M; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Wakatsuki T; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ooki A; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Shinozaki E; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Chin K; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yamaguchi K; Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
J Gastric Cancer ; 23(4): 609-621, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37932227
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastric Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación:
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastric Cancer Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: